<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607813</url>
  </required_header>
  <id_info>
    <org_study_id>CLXH254X2101</org_study_id>
    <secondary_id>2015-003421-33</secondary_id>
    <nct_id>NCT02607813</nct_id>
  </id_info>
  <brief_title>Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations</brief_title>
  <official_title>A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway&#xD;
      Alterations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 18, 2016</start_date>
  <completion_date type="Anticipated">February 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity.</measure>
    <time_frame>From Cycle 1 Day 1 until 30 days for LXH254 single agent and 150 days for LXH254 in combination with PDR001 post study treatment (expected duration approximately 12 months)</time_frame>
    <description>cycle = 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 single agent only)</measure>
    <time_frame>28 days</time_frame>
    <description>cycle = 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 in combination with PDR001 only)</measure>
    <time_frame>56 days</time_frame>
    <description>cycle =28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Every 2 cycles after starting study treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Every 2 cycles after starting study treatment until disease progression; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) - only for dose expansion</measure>
    <time_frame>From time of start treatment until the date of death; expected duration approximately 12 months</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LXH254</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Area Under the Curve (AUC)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: half-life (T1/2)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of pharmacodynamics (PD) marker DUSP6 in tumor tissue and in blood</measure>
    <time_frame>Cycle 1 day 1, 2, 3, 15, and 16; upon disease progression (expected duration approximately 12 months)</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PDR001</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: Area Under the Curve (AUC)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of PDR001: half-life (T1/2)</measure>
    <time_frame>Cycle 1 days 1, 2, 8, and 15; Cycle 2 days 1; Cycle 3 Day 1, 2 and 8; Cycle 4 Day 1; Cycle 5 Day 1; Cycle 6 Day 1</time_frame>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>NSCLC</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation LXH254</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion LXH254: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion LXH254: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion LXH254: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion: LXH254 + PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation LXH254 + PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>pan-RAF inhibitor</description>
    <arm_group_label>Dose escalation LXH254</arm_group_label>
    <arm_group_label>Dose escalation LXH254 + PDR001</arm_group_label>
    <arm_group_label>Dose expansion LXH254: Group 1</arm_group_label>
    <arm_group_label>Dose expansion LXH254: Group 2</arm_group_label>
    <arm_group_label>Dose expansion LXH254: Group 3</arm_group_label>
    <arm_group_label>Dose expansion: LXH254 + PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>Biological: PDR001 anti-PD1 antibody</description>
    <arm_group_label>Dose escalation LXH254 + PDR001</arm_group_label>
    <arm_group_label>Dose expansion: LXH254 + PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients participating in this clinical trial must have progressed following&#xD;
             standard therapy, or for whom, in the opinion of the Investigator, no effective&#xD;
             standard therapy exists, is tolerated or appropriate.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          -  Presence of at least one measurable lesion according to RECIST v1.1.&#xD;
&#xD;
          -  Documented MAPK alteration&#xD;
&#xD;
        Additional inclusion criteria for the Dose Expansion part: LXH254 in combination with&#xD;
        PDR001:&#xD;
&#xD;
          -  Patients with confirmed KRAS-mutated NSCLC&#xD;
&#xD;
          -  Patients with confirmed NRAS-mutated melanoma (cutaneous melanoma only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Prior treatment with a BRAFi, MEKi and/or pan-RAF inihibitors for patients to be enrolled&#xD;
        in the dose expansion part.&#xD;
&#xD;
        Exceptions may be made after documented agreement between Novartis and Investigator.&#xD;
&#xD;
          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO.&#xD;
&#xD;
          -  Any medical condition that would, in the investigator's judgment, prevent the&#xD;
             patient's participation in the clinical study due to safety concerns or compliance&#xD;
             with clinical study procedures.&#xD;
&#xD;
          -  Patients receiving proton pump inhibitors which cannot be discontinued 3 days prior to&#xD;
             the start study treatment and for the duration of the study.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
        Additional exclusion criteria for LXH254 in combination with PDR001&#xD;
&#xD;
          -  History of severe hypersensitivity reactions, which in the opinion of the investigator&#xD;
             may cause in increased risk of serious infusion reaction.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or&#xD;
             chronic infection.&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease.&#xD;
&#xD;
          -  Active infection requiring systemic antibiotic therapy&#xD;
&#xD;
          -  Patients requiring systemic steroid therapy or any immunosuppressive therapy&#xD;
             (≥10mg/day prednisone or equivalent) which cannot be discontinued at least 7 days&#xD;
             prior to first dose of study treatment.&#xD;
&#xD;
          -  Use of any live vaccines against infectious diseases within 4 weeks of initiation of&#xD;
             study treatment.&#xD;
&#xD;
        Other inclusion/exclusion criteria as per protocol may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital MGH Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center SC - LXH254X2101</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT M.D Anderson Cancer Center SC - LXH254X2101</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology, Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LXH254, CRAF, MAPK, solid tumor, PDR001</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

